Grace Therapeutics Statistics
Total Valuation
GRCE has a market cap or net worth of $45.36 million. The enterprise value is $25.35 million.
Important Dates
The last earnings date was Tuesday, August 12, 2025, before market open.
Earnings Date | Aug 12, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
GRCE has 13.83 million shares outstanding. The number of shares has increased by 28.20% in one year.
Current Share Class | 13.83M |
Shares Outstanding | 13.83M |
Shares Change (YoY) | +28.20% |
Shares Change (QoQ) | +15.76% |
Owned by Insiders (%) | 21.58% |
Owned by Institutions (%) | 12.19% |
Float | 7.48M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 0.71 |
P/TBV Ratio | 3.18 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.87
Current Ratio | 8.87 |
Quick Ratio | 8.65 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -16.78% and return on invested capital (ROIC) is -15.06%.
Return on Equity (ROE) | -16.78% |
Return on Assets (ROA) | -13.26% |
Return on Invested Capital (ROIC) | -15.06% |
Return on Capital Employed (ROCE) | -21.94% |
Revenue Per Employee | n/a |
Profits Per Employee | -$1.72M |
Employee Count | 6 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | -2.48M |
Effective Tax Rate | n/a |
Dividends & Yields
GRCE does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -28.20% |
Shareholder Yield | -28.20% |
Earnings Yield | -22.74% |
FCF Yield | -28.90% |
Analyst Forecast
The average price target for GRCE is $12.00, which is 265.85% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $12.00 |
Price Target Difference | 265.85% |
Analyst Consensus | Strong Buy |
Analyst Count | 1 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
The last stock split was on July 10, 2023. It was a reverse split with a ratio of 1:6.
Last Split Date | Jul 10, 2023 |
Split Type | Reverse |
Split Ratio | 1:6 |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 1 |